Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein

Journal of Pharmaceutical Sciences

Volumn 100, Issue 11, 2011, Pages 5007-5017

  Ye, Ling ^a   Wang, Tao ^a   Tang, Lan ^a   Liu, Wei ^a   Yang, Zhen ^b   Zhou, Juan ^a   Zheng, Zhijie ^a   Cai, Zheng ^a   Hu, Ming ^a,b   Liu, Zhongqiu ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Andrographolide; Bioavailability; Caco 2 cells; Intestinal perfusion; MDR1 MDCKII; Metabolism; P glycoprotein; Pharmacokinetics

Indexed keywords

14 DEOXY 12 SULFO ANDROGRAPHOLIDE; ANDROGRAPHOLIDE; DRUG METABOLITE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG PENETRATION; DRUG STABILITY; DRUG TRANSFORMATION; DRUG TRANSPORT; DUODENUM; ILEUM; INTESTINE PERFUSION; JEJUNUM; KIDNEY CELL; LIVER METABOLISM; MALE; NONHUMAN; RAT;

EID: 80053221096     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22693     Document Type: Article

References (30)

1. Yang S, Evens AM, Prachand S, Singh AT, Bhalla S, David K, Gordon LI. Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of andrographis paniculata. Clin Cancer Res 16(19):4755-4768.
2. Trivedi NP, Rawal UM, Patel BP. 2009. Potency of andrographolide as an antitumor compound in BHC-induced liver damage. Integr Cancer Ther 8(2):177-189.
3. Shi MD, Lin HH, Chiang TA, Tsai LY, Tsai SM, Lee YC, Chen JH. 2009. Andrographolide could inhibit human colorectal carcinoma Lovo cells migration and invasion via down-regulation of MMP-7 expression. Chem Biol Interact 180(3):344-352.
4. Hidalgo MA, Romero A, Figueroa J, Cortes P, Concha, II, Hancke JL, Burgos RA. 2005. Andrographolide interferes with binding of nuclear factor-kappaB to DNA in HL-60-derived neutrophilic cells. Br J Pharmacol 144(5):680-686.
5. Geethangili M, Rao YK, Fang SH, Tzeng YM. 2008. Cytotoxic constituents from Andrographis paniculata induce cell cycle arrest in jurkat cells. Phytother Res 22(10):1336-1341.
6. Kim TG, Hwi KK, Hung CS. 2005. Morphological and biochemical changes of andrographolide-induced cell death in human prostatic adenocarcinoma PC-3 cells. In Vivo 19(3):551-557.
7. Liang FP, Lin CH, Kuo CD, Chao HP, Fu SL. 2008. Suppression of v-Src transformation by andrographolide via degradation of the v-Src protein and attenuation of the Erk signaling pathway. J Biol Chem 283(8):5023-5033.
8. Qin LH, Kong L, Shi GJ, Wang ZT, Ge BX. 2006. Andrographolide inhibits the production of TNF-alpha and interleukin-12 in lipopolysaccharide-stimulated macrophages: Role of mitogen-activated protein kinases. Biol Pharm Bull 29(2):220-224.
9. Tsai HR, Yang LM, Tsai WJ, Chiou WF. 2004. Andrographolide acts through inhibition of ERK1/2 and Akt phosphorylation to suppress chemotactic migration. Eur J Pharmacol 498(1-3):45-52.
10. Patarapanich C lS. 2007. HPLC determination of active diterpene lactones from Andrographis paniculata Nees planted in various seasons and regions in Thailand. Thai J Pharm Sci 31(91-9).
11. Woo AY, Waye MM, Tsui SK, Yeung ST, Cheng CH. 2008. Andrographolide up-regulates cellular-reduced glutathione level and protects cardiomyocytes against hypoxia/reoxygenation injury. J Pharmacol Exp Ther 325(1):226-235.
12. Zhao F, He EQ, Wang L, Liu K. 2008. Anti-tumor activities of andrographolide, a diterpene from Andrographis paniculata, by inducing apoptosis and inhibiting VEGF level. J Asian Nat Prod Res 10(5-6):467-473.
13. Raina AP KA. 2007. HPTLC analysis of hepatoprotective diterpenoid andrographolide from Andrographis paniculata Nees (Kalmegh). Ind J Pharm Sci 69:473-475.
14. Singh RP, Banerjee S, Rao AR. 2001. Modulatory influence of Andrographis paniculata on mouse hepatic and extrahepatic carcinogen metabolizing enzymes and antioxidant status. Phytother Res 15(5):382-390.
15. Panossian A, Hovhannisyan A, Mamikonyan G, Abrahamian H, Hambardzumyan E, Gabrielian E, Goukasova G, Wikman G, Wagner H. 2000. Pharmacokinetic and oral bioavailability of andrographolide from Andrographis paniculata fixed combination Kan Jang in rats and human. Phytomedicine 7(5):351-364.
16. Suo XB, Zhang H, Wang YQ. 2007. HPLC determination of andrographolide in rat whole blood: Study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. Biomed Chromatogr 21(7):730-734.
17. Xu L, Xiao DW, Lou S, Zou JJ, Zhu YB, Fan HW, Wang GJ. 2009. A simple and sensitive HPLC-ESI-MS/MS method for the determination of andrographolide in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 877(5-6):502-506.
18. He X, Li J, Gao H, Qiu F, Hu K, Cui X, Yao X. 2003. Identification of a rare sulfonic acid metabolite of andrographolide in rats. Drug Metab Dispos 31(8):983-985.
19. Meng ZM. 1981. Studies on the structure of the adduct of andrographolide with sodium hydrogen sulfite (author's transl). Yao Xue Xue Bao 16(8):571-575.
20. Cui L, Qiu F, Wang N, Yao X. 2004. Four new andrographolide metabolites in human urine. Chem Pharm Bull (Tokyo) 52(6):772-775.
21. Hu M, Chen J, Lin H. 2003. Metabolism of flavonoids via enteric recycling: Mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. J Pharmacol Exp Ther 307(1):314-321.
22. Hu M, Chen J, Tran D, Zhu Y, Leonardo G. 1994. The Caco-2 cell monolayers as an intestinal metabolism model: Metabolism of dipeptide Phe-Pro. J Drug Target 2(1):79-89.
23. Hu M, Chen J, Zhu Y, Dantzig AH, Stratford RE, Jr., Kuhfeld MT. 1994. Mechanism and kinetics of transcellular transport of a new beta-lactam antibiotic loracarbef across an intestinal epithelial membrane model system (Caco-2). Pharm Res 11(10):1405-1413.
24. Hu M, Roland K, Ge L, Chen J, Li Y, Tyle P, Roy S. 1998. Determination of absorption characteristics of AG337, a novel thymidylate synthase inhibitor, using a perfused rat intestinal model. J Pharm Sci 87(7):886-890.
25. Liu ZQ, Jiang ZH, Liu L, Hu M. 2006. Mechanisms responsible for poor oral bioavailability of paeoniflorin: Role of intestinal disposition and interactions with sinomenine. Pharm Res 23(12):2768-2780.
26. Guidance for industry. 2001. Bioanalytical method validation, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER).
27. Artursson P, Karlsson J. 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175(3):880-885.
28. Yi L, Bandu ML, Desaire H. 2005. Identifying lactone hydrolysis in pharmaceuticals. A tool for metabolite structural characterization. Anal Chem 77(20):6655-6663.
29. Zhang Y, Gupta A, Wang H, Zhou L, Vethanayagam RR, Unadkat JD, Mao Q. 2005. BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 22(12):2023-2034.
30. Ho GT, Moodie FM, Satsangi J. 2003. Multidrug resistance 1 gene (P-glycoprotein 170): An important determinant in gastrointestinal disease? Gut 52(5):759-766.